Plain-English translation of NCT07129564 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →This study is testing whether sacubitril/valsartan—a heart medication that works on the heart's structure and function—can help people with persistent atrial fibrillation (an irregular heartbeat) stay in normal rhythm after treatment. All participants will first receive standard treatment (either medication or electrical shock) to restore normal heart rhythm. Then, some participants will take this medication along with a standard anti-arrhythmia drug, while others will take only the standard drug. The study will track whether the medication helps prevent the irregular heartbeat from returning and whether it reduces scarring and enlargement of the heart chamber.
Persistent atrial fibrillation causes the heart to develop scarring and structural damage over time, which makes the condition harder to treat and increases the risk of stroke and heart failure. This study is exploring whether this medication can reverse some of that damage and help people maintain a normal heartbeat long-term after cardioversion.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will first undergo treatment (medication or electrical cardioversion) to restore your normal heart rhythm. Then you will be randomly assigned to take either the test medication plus a standard heart rhythm drug, or the standard drug alone. You will have regular follow-up visits where doctors will monitor your heart rhythm, take heart imaging scans (including special MRI scans) to measure any changes in your heart's structure, and check for side effects. The study involves about 480 participants across multiple centers and tracks whether you maintain normal rhythm and how your heart structure changes over time.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China